Fate Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that management will present at two upcoming investor conferences in October:
- 2018 Cantor Global Healthcare Conference at 9:10 a.m. ET on Tuesday, October 2, 2018 in New York City.
- Leerink Partners Roundtable Series: Rare Disease & Oncology at 8:30 a.m. ET on Wednesday, October 3, 2018 in New York City.
Live webcasts of the presentations will be available through the investor relations section of the Company's website at . Following the live webcasts, an archived replay will be available on the Company's website.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company is pioneering the development of off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology pipeline is comprised of FATE-NK100, a donor-derived natural killer (NK) cell cancer immunotherapy that is currently being evaluated in three Phase 1 clinical trials, as well as iPSC-derived NK cell and T-cell immunotherapies, with a focus on developing augmented cell products intended to synergize with checkpoint inhibitor and monoclonal antibody therapies and to target tumor-specific antigens. The Company’s immuno-regulatory pipeline includes ProTmune™, a next-generation donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders.
Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
